Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 23 h ago

Amylyx Pharmaceuticals, Inc.: Commodore Capital LP amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Commodore Capital LP amended its Schedule 13G filing on Amylyx Pharmaceuticals, disclosing a revised stake in the company under SEC accession 0001831942-26-000054. The filing updates the investment firm's previously reported ownership position in the biopharmaceutical company. Schedule 13G amendments are typically filed by investors holding passive stakes of 5% or more, though the headline did not specify the exact percentage or share count in the revised filing. The change matters because it signals a shift in a major institutional holder's position in Amylyx, which investors track for clues about sentiment toward the stock. What to watch next is the full filing details, including the precise ownership percentage and any change in share count versus the prior disclosure.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Amylyx Pharmaceuticals, Inc., Commodore Capital LP